ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study)

Mauro Neri, Anna Lorenzin, Massimo de Cal, Alessandra Brendolan, Nicola Marchionna, Sara Samoni, Monica Zanella, Silvia De Rosa, Francesca Martino, Zaccaria Ricci, Javier Maynar, Georg Auzinger, Gianluca Villa, Didier Payen, Michael Joannidis, Claudio Ronco

Research output: Contribution to journalArticle

Abstract

BACKGROUND: ACUsmart (Medica S.P.A., Italy) is a new-generation, continuous renal replacement therapy (CRRT) machine for critically ill patients with acute kidney injury. We designed a multicenter international pilot study to provide a description of outlines of the ACUsmart system, evaluation aspects of functionality, usability, and feasibility, discriminating reasons of possible treatment's withdrawals or discontinuations and highlighting strong and weak points of the machine.

METHODS: Data of 23 CRRT (and 11 plasma exchange) treatments were collected from 4 intensive care units. Parameters such as treatment duration, downtime, delivered dose, and number and type of alarms were recorded. The general perception of the machine was quantified through the administration of a survey to each component of the evaluating staff.

RESULTS: A total treatment time of 447 h was carried with ACUsmart. Eleven continuous veno-venous hemofiltration, 4 continuous veno-venous hemodialysis , and 8 continuous veno-venous hemodiafiltration were performed. The average percentage of net treatment duration with respect to total treatment duration was 92.37%. The mean prescribed dose and delivered dose were 26.33 and 24.10 mL/kg/h, respectively. In general, the machine was rated by users involved as practical and easy to use, although few components need to be slightly improved.

CONCLUSION: ACUsmart is a new multifunctional machine that meets most of the features required in a fourth-generation CRRT equipment.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalBlood Purification
DOIs
Publication statusE-pub ahead of print - Feb 1 2019

Fingerprint

Renal Replacement Therapy
Adenosine Monophosphate
Multicenter Studies
Therapeutics
Hemodiafiltration
Hemofiltration
Plasma Exchange
Acute Kidney Injury
Critical Illness
Italy
Intensive Care Units
Renal Dialysis
Equipment and Supplies

Cite this

ACUsmart Continuous Renal Replacement Therapy Platform : Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study). / Neri, Mauro; Lorenzin, Anna; de Cal, Massimo; Brendolan, Alessandra; Marchionna, Nicola; Samoni, Sara; Zanella, Monica; De Rosa, Silvia; Martino, Francesca; Ricci, Zaccaria; Maynar, Javier; Auzinger, Georg; Villa, Gianluca; Payen, Didier; Joannidis, Michael; Ronco, Claudio.

In: Blood Purification, 01.02.2019, p. 1-7.

Research output: Contribution to journalArticle

Neri, M, Lorenzin, A, de Cal, M, Brendolan, A, Marchionna, N, Samoni, S, Zanella, M, De Rosa, S, Martino, F, Ricci, Z, Maynar, J, Auzinger, G, Villa, G, Payen, D, Joannidis, M & Ronco, C 2019, 'ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study)', Blood Purification, pp. 1-7. https://doi.org/10.1159/000496090
Neri, Mauro ; Lorenzin, Anna ; de Cal, Massimo ; Brendolan, Alessandra ; Marchionna, Nicola ; Samoni, Sara ; Zanella, Monica ; De Rosa, Silvia ; Martino, Francesca ; Ricci, Zaccaria ; Maynar, Javier ; Auzinger, Georg ; Villa, Gianluca ; Payen, Didier ; Joannidis, Michael ; Ronco, Claudio. / ACUsmart Continuous Renal Replacement Therapy Platform : Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study). In: Blood Purification. 2019 ; pp. 1-7.
@article{3501ef79659e477a8149e8470c4fda5b,
title = "ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study)",
abstract = "BACKGROUND: ACUsmart (Medica S.P.A., Italy) is a new-generation, continuous renal replacement therapy (CRRT) machine for critically ill patients with acute kidney injury. We designed a multicenter international pilot study to provide a description of outlines of the ACUsmart system, evaluation aspects of functionality, usability, and feasibility, discriminating reasons of possible treatment's withdrawals or discontinuations and highlighting strong and weak points of the machine.METHODS: Data of 23 CRRT (and 11 plasma exchange) treatments were collected from 4 intensive care units. Parameters such as treatment duration, downtime, delivered dose, and number and type of alarms were recorded. The general perception of the machine was quantified through the administration of a survey to each component of the evaluating staff.RESULTS: A total treatment time of 447 h was carried with ACUsmart. Eleven continuous veno-venous hemofiltration, 4 continuous veno-venous hemodialysis , and 8 continuous veno-venous hemodiafiltration were performed. The average percentage of net treatment duration with respect to total treatment duration was 92.37{\%}. The mean prescribed dose and delivered dose were 26.33 and 24.10 mL/kg/h, respectively. In general, the machine was rated by users involved as practical and easy to use, although few components need to be slightly improved.CONCLUSION: ACUsmart is a new multifunctional machine that meets most of the features required in a fourth-generation CRRT equipment.",
author = "Mauro Neri and Anna Lorenzin and {de Cal}, Massimo and Alessandra Brendolan and Nicola Marchionna and Sara Samoni and Monica Zanella and {De Rosa}, Silvia and Francesca Martino and Zaccaria Ricci and Javier Maynar and Georg Auzinger and Gianluca Villa and Didier Payen and Michael Joannidis and Claudio Ronco",
note = "{\circledC} 2019 The Author(s) Published by S. Karger AG, Basel.",
year = "2019",
month = "2",
day = "1",
doi = "10.1159/000496090",
language = "English",
pages = "1--7",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - ACUsmart Continuous Renal Replacement Therapy Platform

T2 - Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study)

AU - Neri, Mauro

AU - Lorenzin, Anna

AU - de Cal, Massimo

AU - Brendolan, Alessandra

AU - Marchionna, Nicola

AU - Samoni, Sara

AU - Zanella, Monica

AU - De Rosa, Silvia

AU - Martino, Francesca

AU - Ricci, Zaccaria

AU - Maynar, Javier

AU - Auzinger, Georg

AU - Villa, Gianluca

AU - Payen, Didier

AU - Joannidis, Michael

AU - Ronco, Claudio

N1 - © 2019 The Author(s) Published by S. Karger AG, Basel.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - BACKGROUND: ACUsmart (Medica S.P.A., Italy) is a new-generation, continuous renal replacement therapy (CRRT) machine for critically ill patients with acute kidney injury. We designed a multicenter international pilot study to provide a description of outlines of the ACUsmart system, evaluation aspects of functionality, usability, and feasibility, discriminating reasons of possible treatment's withdrawals or discontinuations and highlighting strong and weak points of the machine.METHODS: Data of 23 CRRT (and 11 plasma exchange) treatments were collected from 4 intensive care units. Parameters such as treatment duration, downtime, delivered dose, and number and type of alarms were recorded. The general perception of the machine was quantified through the administration of a survey to each component of the evaluating staff.RESULTS: A total treatment time of 447 h was carried with ACUsmart. Eleven continuous veno-venous hemofiltration, 4 continuous veno-venous hemodialysis , and 8 continuous veno-venous hemodiafiltration were performed. The average percentage of net treatment duration with respect to total treatment duration was 92.37%. The mean prescribed dose and delivered dose were 26.33 and 24.10 mL/kg/h, respectively. In general, the machine was rated by users involved as practical and easy to use, although few components need to be slightly improved.CONCLUSION: ACUsmart is a new multifunctional machine that meets most of the features required in a fourth-generation CRRT equipment.

AB - BACKGROUND: ACUsmart (Medica S.P.A., Italy) is a new-generation, continuous renal replacement therapy (CRRT) machine for critically ill patients with acute kidney injury. We designed a multicenter international pilot study to provide a description of outlines of the ACUsmart system, evaluation aspects of functionality, usability, and feasibility, discriminating reasons of possible treatment's withdrawals or discontinuations and highlighting strong and weak points of the machine.METHODS: Data of 23 CRRT (and 11 plasma exchange) treatments were collected from 4 intensive care units. Parameters such as treatment duration, downtime, delivered dose, and number and type of alarms were recorded. The general perception of the machine was quantified through the administration of a survey to each component of the evaluating staff.RESULTS: A total treatment time of 447 h was carried with ACUsmart. Eleven continuous veno-venous hemofiltration, 4 continuous veno-venous hemodialysis , and 8 continuous veno-venous hemodiafiltration were performed. The average percentage of net treatment duration with respect to total treatment duration was 92.37%. The mean prescribed dose and delivered dose were 26.33 and 24.10 mL/kg/h, respectively. In general, the machine was rated by users involved as practical and easy to use, although few components need to be slightly improved.CONCLUSION: ACUsmart is a new multifunctional machine that meets most of the features required in a fourth-generation CRRT equipment.

U2 - 10.1159/000496090

DO - 10.1159/000496090

M3 - Article

C2 - 30712031

SP - 1

EP - 7

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

ER -